Konstantinos Votanopoulos
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Peritoneal Neoplasms | 44 | 2020 | 265 | 11.370 |
Why?
|
| Hyperthermia, Induced | 42 | 2020 | 245 | 11.110 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 31 | 2020 | 155 | 7.490 |
Why?
|
| Appendiceal Neoplasms | 21 | 2020 | 99 | 6.030 |
Why?
|
| Sarcoma | 22 | 2021 | 94 | 5.430 |
Why?
|
| Stomach Neoplasms | 36 | 2019 | 114 | 5.120 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 24 | 2020 | 491 | 4.910 |
Why?
|
| Neoplasm Recurrence, Local | 29 | 2020 | 402 | 4.600 |
Why?
|
| Adenocarcinoma | 33 | 2018 | 321 | 3.900 |
Why?
|
| Survival Rate | 64 | 2020 | 928 | 3.240 |
Why?
|
| Gastrectomy | 29 | 2019 | 70 | 3.100 |
Why?
|
| Antineoplastic Agents | 17 | 2020 | 628 | 2.860 |
Why?
|
| Prognosis | 62 | 2020 | 1606 | 2.570 |
Why?
|
| Retrospective Studies | 71 | 2020 | 3825 | 2.570 |
Why?
|
| Combined Modality Therapy | 35 | 2020 | 590 | 2.530 |
Why?
|
| Neoplasm Staging | 45 | 2019 | 486 | 2.390 |
Why?
|
| Follow-Up Studies | 49 | 2020 | 2367 | 2.380 |
Why?
|
| Adrenocortical Carcinoma | 18 | 2019 | 35 | 2.240 |
Why?
|
| Adrenal Cortex Neoplasms | 18 | 2019 | 36 | 2.240 |
Why?
|
| Middle Aged | 107 | 2020 | 12726 | 2.130 |
Why?
|
| Organoids | 6 | 2020 | 99 | 2.120 |
Why?
|
| Postoperative Complications | 23 | 2020 | 850 | 2.050 |
Why?
|
| Retroperitoneal Neoplasms | 7 | 2020 | 19 | 1.980 |
Why?
|
| Neoplasms | 8 | 2020 | 793 | 1.910 |
Why?
|
| Humans | 142 | 2021 | 34562 | 1.890 |
Why?
|
| Male | 118 | 2020 | 20739 | 1.880 |
Why?
|
| Lymph Node Excision | 11 | 2019 | 98 | 1.820 |
Why?
|
| Female | 118 | 2020 | 21531 | 1.800 |
Why?
|
| Chemotherapy, Adjuvant | 22 | 2019 | 214 | 1.620 |
Why?
|
| Mesothelioma | 5 | 2019 | 37 | 1.500 |
Why?
|
| Aged | 77 | 2020 | 11022 | 1.480 |
Why?
|
| Drug Screening Assays, Antitumor | 4 | 2019 | 57 | 1.470 |
Why?
|
| Lymph Nodes | 8 | 2020 | 120 | 1.370 |
Why?
|
| Prospective Studies | 23 | 2020 | 2463 | 1.360 |
Why?
|
| Adult | 65 | 2020 | 10030 | 1.360 |
Why?
|
| Extremities | 8 | 2020 | 55 | 1.360 |
Why?
|
| Carcinoma | 5 | 2016 | 97 | 1.350 |
Why?
|
| Soft Tissue Neoplasms | 6 | 2021 | 48 | 1.280 |
Why?
|
| Colonic Neoplasms | 3 | 2016 | 77 | 1.280 |
Why?
|
| Pancreatectomy | 4 | 2019 | 25 | 1.250 |
Why?
|
| Melanoma | 3 | 2019 | 170 | 1.240 |
Why?
|
| Mitomycin | 7 | 2020 | 51 | 1.110 |
Why?
|
| Adenocarcinoma, Mucinous | 5 | 2020 | 29 | 1.090 |
Why?
|
| Models, Biological | 2 | 2019 | 432 | 1.010 |
Why?
|
| Morbidity | 9 | 2017 | 103 | 0.990 |
Why?
|
| Aged, 80 and over | 30 | 2020 | 4157 | 0.920 |
Why?
|
| Neoadjuvant Therapy | 5 | 2020 | 71 | 0.860 |
Why?
|
| United States | 43 | 2020 | 4278 | 0.850 |
Why?
|
| Radiotherapy, Adjuvant | 5 | 2020 | 89 | 0.820 |
Why?
|
| Adrenalectomy | 8 | 2018 | 33 | 0.810 |
Why?
|
| Abdominal Neoplasms | 4 | 2018 | 14 | 0.780 |
Why?
|
| Colorectal Neoplasms | 8 | 2020 | 232 | 0.780 |
Why?
|
| Treatment Outcome | 25 | 2020 | 3623 | 0.770 |
Why?
|
| Splenectomy | 4 | 2019 | 23 | 0.750 |
Why?
|
| Young Adult | 18 | 2020 | 2831 | 0.750 |
Why?
|
| Peritoneum | 4 | 2020 | 34 | 0.730 |
Why?
|
| Survival Analysis | 15 | 2020 | 510 | 0.700 |
Why?
|
| Registries | 3 | 2018 | 328 | 0.640 |
Why?
|
| Skin Neoplasms | 2 | 2019 | 225 | 0.640 |
Why?
|
| Adaptive Immunity | 1 | 2020 | 16 | 0.630 |
Why?
|
| Databases, Factual | 12 | 2020 | 380 | 0.620 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2019 | 60 | 0.610 |
Why?
|
| Liver Neoplasms | 3 | 2018 | 170 | 0.590 |
Why?
|
| Organoplatinum Compounds | 3 | 2013 | 46 | 0.560 |
Why?
|
| Quality of Life | 7 | 2020 | 1032 | 0.540 |
Why?
|
| Intensive Care Units | 2 | 2015 | 123 | 0.540 |
Why?
|
| Diaphragm | 2 | 2014 | 39 | 0.530 |
Why?
|
| Intestinal Perforation | 1 | 2016 | 10 | 0.500 |
Why?
|
| Lymphatic Metastasis | 12 | 2018 | 176 | 0.500 |
Why?
|
| Cell Proliferation | 1 | 2018 | 633 | 0.480 |
Why?
|
| Linitis Plastica | 1 | 2015 | 2 | 0.470 |
Why?
|
| Ovarian Neoplasms | 1 | 2016 | 114 | 0.460 |
Why?
|
| Peritoneal Stomata | 1 | 2015 | 3 | 0.460 |
Why?
|
| Patient Admission | 1 | 2015 | 59 | 0.450 |
Why?
|
| Immunotherapy | 3 | 2020 | 96 | 0.440 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2014 | 12 | 0.430 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2014 | 40 | 0.430 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 922 | 0.430 |
Why?
|
| Abdominal Cavity | 1 | 2014 | 6 | 0.430 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2014 | 34 | 0.420 |
Why?
|
| Gallbladder Neoplasms | 1 | 2014 | 35 | 0.420 |
Why?
|
| Length of Stay | 6 | 2020 | 335 | 0.410 |
Why?
|
| Ascites | 1 | 2013 | 15 | 0.400 |
Why?
|
| Urinary Tract | 1 | 2013 | 31 | 0.400 |
Why?
|
| Laparoscopy | 3 | 2019 | 194 | 0.400 |
Why?
|
| Urologic Diseases | 1 | 2013 | 35 | 0.400 |
Why?
|
| Reoperation | 6 | 2017 | 265 | 0.390 |
Why?
|
| Rectal Neoplasms | 1 | 2013 | 21 | 0.390 |
Why?
|
| Nomograms | 3 | 2020 | 35 | 0.380 |
Why?
|
| Infusions, Parenteral | 5 | 2016 | 69 | 0.380 |
Why?
|
| Feasibility Studies | 3 | 2019 | 323 | 0.370 |
Why?
|
| Adolescent | 9 | 2020 | 3805 | 0.370 |
Why?
|
| Neutrophils | 3 | 2020 | 123 | 0.350 |
Why?
|
| Risk Factors | 14 | 2020 | 4137 | 0.350 |
Why?
|
| Diabetes Mellitus | 1 | 2014 | 439 | 0.340 |
Why?
|
| Hepatectomy | 3 | 2018 | 57 | 0.340 |
Why?
|
| Disease-Free Survival | 11 | 2019 | 354 | 0.320 |
Why?
|
| Vena Cava, Inferior | 1 | 2009 | 30 | 0.310 |
Why?
|
| Abdominal Injuries | 1 | 2009 | 32 | 0.300 |
Why?
|
| Cystadenoma | 1 | 2009 | 2 | 0.300 |
Why?
|
| Cisplatin | 3 | 2014 | 88 | 0.300 |
Why?
|
| Wounds, Gunshot | 1 | 2009 | 35 | 0.300 |
Why?
|
| Biliary Tract Neoplasms | 1 | 2009 | 10 | 0.300 |
Why?
|
| Radiography, Thoracic | 2 | 2019 | 44 | 0.290 |
Why?
|
| Abdominal Pain | 1 | 2009 | 44 | 0.290 |
Why?
|
| Lymphocytes | 2 | 2020 | 59 | 0.270 |
Why?
|
| Patient Readmission | 4 | 2016 | 141 | 0.270 |
Why?
|
| Perfusion | 2 | 2020 | 78 | 0.270 |
Why?
|
| Cohort Studies | 12 | 2019 | 1910 | 0.260 |
Why?
|
| Propoxur | 1 | 2007 | 1 | 0.260 |
Why?
|
| Child | 4 | 2014 | 2614 | 0.260 |
Why?
|
| Pancreatitis | 1 | 2007 | 20 | 0.260 |
Why?
|
| Insecticides | 1 | 2007 | 22 | 0.260 |
Why?
|
| Psychomotor Performance | 1 | 2008 | 116 | 0.260 |
Why?
|
| General Surgery | 1 | 2008 | 85 | 0.260 |
Why?
|
| Propensity Score | 4 | 2019 | 51 | 0.250 |
Why?
|
| Proportional Hazards Models | 9 | 2020 | 804 | 0.250 |
Why?
|
| Obesity | 2 | 2014 | 1246 | 0.250 |
Why?
|
| Multivariate Analysis | 5 | 2015 | 703 | 0.240 |
Why?
|
| Preoperative Care | 4 | 2015 | 129 | 0.240 |
Why?
|
| Neoplasm Invasiveness | 6 | 2017 | 197 | 0.240 |
Why?
|
| Blood Transfusion | 2 | 2017 | 76 | 0.240 |
Why?
|
| Decision Support Techniques | 2 | 2018 | 136 | 0.240 |
Why?
|
| Carcinoma, Signet Ring Cell | 2 | 2015 | 6 | 0.230 |
Why?
|
| Body Mass Index | 3 | 2020 | 954 | 0.220 |
Why?
|
| Postural Balance | 1 | 2016 | 152 | 0.210 |
Why?
|
| North Carolina | 3 | 2016 | 1613 | 0.200 |
Why?
|
| Blood Platelets | 2 | 2015 | 61 | 0.200 |
Why?
|
| Risk Assessment | 3 | 2018 | 1508 | 0.200 |
Why?
|
| Pesticides | 1 | 2016 | 201 | 0.200 |
Why?
|
| Carboplatin | 2 | 2013 | 55 | 0.200 |
Why?
|
| Limb Salvage | 2 | 2020 | 24 | 0.200 |
Why?
|
| Occupational Exposure | 1 | 2016 | 237 | 0.200 |
Why?
|
| Emigrants and Immigrants | 1 | 2016 | 248 | 0.190 |
Why?
|
| Transients and Migrants | 1 | 2016 | 304 | 0.190 |
Why?
|
| Cell Survival | 2 | 2019 | 304 | 0.170 |
Why?
|
| Case-Control Studies | 3 | 2016 | 926 | 0.170 |
Why?
|
| Health Status | 3 | 2019 | 411 | 0.160 |
Why?
|
| Leukocyte Count | 1 | 2020 | 50 | 0.160 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2019 | 988 | 0.160 |
Why?
|
| Hispanic Americans | 1 | 2016 | 948 | 0.160 |
Why?
|
| Neoplasm, Residual | 2 | 2016 | 27 | 0.150 |
Why?
|
| Patient Selection | 2 | 2020 | 291 | 0.150 |
Why?
|
| Meta-Analysis as Topic | 1 | 2019 | 48 | 0.150 |
Why?
|
| Neoplasm Metastasis | 2 | 2019 | 234 | 0.150 |
Why?
|
| Incidental Findings | 1 | 2018 | 26 | 0.140 |
Why?
|
| Thoracic Neoplasms | 1 | 2018 | 6 | 0.140 |
Why?
|
| Tumor Cells, Cultured | 1 | 2018 | 180 | 0.140 |
Why?
|
| Caregivers | 1 | 2020 | 116 | 0.140 |
Why?
|
| Rare Diseases | 1 | 2018 | 21 | 0.140 |
Why?
|
| Interinstitutional Relations | 1 | 2018 | 13 | 0.140 |
Why?
|
| Kidney Neoplasms | 1 | 2020 | 205 | 0.140 |
Why?
|
| Thorax | 1 | 2018 | 32 | 0.140 |
Why?
|
| Age Factors | 5 | 2020 | 1262 | 0.140 |
Why?
|
| Pilot Projects | 1 | 2019 | 585 | 0.140 |
Why?
|
| Incidence | 6 | 2016 | 1290 | 0.130 |
Why?
|
| Anesthesia, Conduction | 1 | 2018 | 27 | 0.130 |
Why?
|
| Cooperative Behavior | 1 | 2018 | 87 | 0.130 |
Why?
|
| Hospital Mortality | 2 | 2016 | 207 | 0.130 |
Why?
|
| Esophagogastric Junction | 1 | 2017 | 10 | 0.130 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2019 | 565 | 0.120 |
Why?
|
| Tumor Burden | 4 | 2017 | 65 | 0.120 |
Why?
|
| Esophageal Neoplasms | 1 | 2017 | 44 | 0.120 |
Why?
|
| Depression | 1 | 2020 | 458 | 0.120 |
Why?
|
| Mitotane | 1 | 2015 | 2 | 0.120 |
Why?
|
| Gastric Stump | 1 | 2015 | 2 | 0.120 |
Why?
|
| Helicobacter Infections | 1 | 2015 | 9 | 0.120 |
Why?
|
| Gastroenterostomy | 1 | 2015 | 2 | 0.120 |
Why?
|
| Anastomosis, Roux-en-Y | 1 | 2015 | 6 | 0.120 |
Why?
|
| Abdomen | 1 | 2016 | 52 | 0.120 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2015 | 46 | 0.120 |
Why?
|
| Jejunostomy | 1 | 2015 | 8 | 0.120 |
Why?
|
| Esophagectomy | 1 | 2015 | 18 | 0.120 |
Why?
|
| Forecasting | 1 | 2016 | 153 | 0.110 |
Why?
|
| Immunoenzyme Techniques | 1 | 2015 | 56 | 0.110 |
Why?
|
| Odds Ratio | 4 | 2020 | 480 | 0.110 |
Why?
|
| Enteral Nutrition | 1 | 2015 | 30 | 0.110 |
Why?
|
| Lung Neoplasms | 1 | 2019 | 455 | 0.110 |
Why?
|
| Predictive Value of Tests | 4 | 2020 | 939 | 0.110 |
Why?
|
| Anemia | 1 | 2015 | 58 | 0.110 |
Why?
|
| Drainage | 1 | 2015 | 66 | 0.110 |
Why?
|
| Intraoperative Care | 1 | 2015 | 55 | 0.110 |
Why?
|
| Cardia | 1 | 2014 | 1 | 0.110 |
Why?
|
| Skilled Nursing Facilities | 1 | 2014 | 13 | 0.110 |
Why?
|
| Time Factors | 2 | 2017 | 2353 | 0.110 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2014 | 10 | 0.110 |
Why?
|
| Frozen Sections | 1 | 2014 | 19 | 0.110 |
Why?
|
| Injections, Intraperitoneal | 1 | 2014 | 51 | 0.110 |
Why?
|
| Pneumonia | 1 | 2014 | 70 | 0.110 |
Why?
|
| Omentum | 1 | 2014 | 26 | 0.110 |
Why?
|
| Colectomy | 1 | 2014 | 30 | 0.110 |
Why?
|
| Appendix | 1 | 2014 | 6 | 0.110 |
Why?
|
| Thrombosis | 1 | 2014 | 88 | 0.110 |
Why?
|
| Respiratory Insufficiency | 1 | 2014 | 61 | 0.100 |
Why?
|
| Thiosulfates | 1 | 2013 | 3 | 0.100 |
Why?
|
| Endosonography | 1 | 2014 | 55 | 0.100 |
Why?
|
| Pseudomyxoma Peritonei | 1 | 2013 | 13 | 0.100 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2014 | 103 | 0.100 |
Why?
|
| Logistic Models | 4 | 2018 | 808 | 0.100 |
Why?
|
| Reconstructive Surgical Procedures | 1 | 2015 | 202 | 0.100 |
Why?
|
| Ovariectomy | 1 | 2014 | 204 | 0.100 |
Why?
|
| Ethnic Groups | 1 | 2016 | 483 | 0.100 |
Why?
|
| Patient Discharge | 1 | 2014 | 214 | 0.100 |
Why?
|
| Disease Progression | 1 | 2014 | 634 | 0.090 |
Why?
|
| Analysis of Variance | 2 | 2015 | 508 | 0.090 |
Why?
|
| European Continental Ancestry Group | 1 | 2016 | 1176 | 0.090 |
Why?
|
| Liver | 2 | 2015 | 513 | 0.090 |
Why?
|
| Drug Therapy, Combination | 1 | 2012 | 318 | 0.080 |
Why?
|
| Medical Oncology | 1 | 2011 | 94 | 0.080 |
Why?
|
| Ligation | 1 | 2009 | 65 | 0.080 |
Why?
|
| Amputation | 1 | 2009 | 44 | 0.080 |
Why?
|
| Compartment Syndromes | 1 | 2009 | 38 | 0.080 |
Why?
|
| Leg | 1 | 2009 | 71 | 0.080 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2009 | 6 | 0.080 |
Why?
|
| Lymphocyte Count | 2 | 2020 | 25 | 0.070 |
Why?
|
| Mediastinal Cyst | 1 | 2007 | 3 | 0.070 |
Why?
|
| Cross-Over Studies | 1 | 2008 | 100 | 0.070 |
Why?
|
| Diagnosis, Differential | 1 | 2009 | 542 | 0.070 |
Why?
|
| Administration, Inhalation | 1 | 2007 | 56 | 0.060 |
Why?
|
| Fluid Therapy | 1 | 2007 | 25 | 0.060 |
Why?
|
| Mental Health | 2 | 2019 | 126 | 0.060 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2008 | 82 | 0.060 |
Why?
|
| Education, Medical, Graduate | 1 | 2008 | 138 | 0.060 |
Why?
|
| Genetic Markers | 2 | 2018 | 132 | 0.060 |
Why?
|
| Computer Simulation | 1 | 2008 | 256 | 0.060 |
Why?
|
| Gene Expression Profiling | 2 | 2020 | 341 | 0.060 |
Why?
|
| Blood Loss, Surgical | 2 | 2015 | 55 | 0.050 |
Why?
|
| Internship and Residency | 1 | 2008 | 330 | 0.050 |
Why?
|
| Rectal Diseases | 1 | 2002 | 2 | 0.050 |
Why?
|
| Cysts | 1 | 2002 | 18 | 0.050 |
Why?
|
| Quality Assurance, Health Care | 1 | 2020 | 76 | 0.040 |
Why?
|
| Immune System Phenomena | 1 | 2020 | 5 | 0.040 |
Why?
|
| Oncogenes | 1 | 2020 | 14 | 0.040 |
Why?
|
| Intestinal Obstruction | 1 | 2020 | 12 | 0.040 |
Why?
|
| Cost of Illness | 1 | 2020 | 74 | 0.040 |
Why?
|
| Disease Management | 1 | 2020 | 134 | 0.040 |
Why?
|
| Nephrectomy | 1 | 2020 | 127 | 0.040 |
Why?
|
| Palliative Care | 1 | 2020 | 52 | 0.040 |
Why?
|
| Quality of Health Care | 1 | 2020 | 159 | 0.040 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2019 | 24 | 0.040 |
Why?
|
| Lower Extremity | 1 | 2020 | 106 | 0.040 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2019 | 74 | 0.040 |
Why?
|
| Wound Healing | 1 | 2020 | 190 | 0.040 |
Why?
|
| Retroperitoneal Space | 1 | 2018 | 20 | 0.040 |
Why?
|
| Bone Neoplasms | 1 | 2020 | 122 | 0.040 |
Why?
|
| Health Care Costs | 1 | 2019 | 126 | 0.030 |
Why?
|
| Hydrogels | 1 | 2019 | 127 | 0.030 |
Why?
|
| Renal Dialysis | 1 | 2020 | 282 | 0.030 |
Why?
|
| Blood Cell Count | 1 | 2018 | 30 | 0.030 |
Why?
|
| Appendectomy | 1 | 2018 | 19 | 0.030 |
Why?
|
| Health Services Research | 1 | 2018 | 82 | 0.030 |
Why?
|
| Renal Insufficiency | 1 | 2018 | 58 | 0.030 |
Why?
|
| Venous Thromboembolism | 1 | 2018 | 29 | 0.030 |
Why?
|
| ROC Curve | 1 | 2018 | 176 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2018 | 168 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2019 | 781 | 0.030 |
Why?
|
| Inflammation | 1 | 2020 | 557 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2018 | 614 | 0.030 |
Why?
|
| Heart Diseases | 1 | 2017 | 124 | 0.030 |
Why?
|
| Emotions | 1 | 2016 | 60 | 0.030 |
Why?
|
| Pancreatic Fistula | 1 | 2016 | 4 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2016 | 104 | 0.030 |
Why?
|
| Extracellular Matrix | 1 | 2018 | 261 | 0.030 |
Why?
|
| Helicobacter pylori | 1 | 2015 | 8 | 0.030 |
Why?
|
| Hydrocortisone | 1 | 2015 | 61 | 0.030 |
Why?
|
| Platelet Count | 1 | 2015 | 25 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2015 | 128 | 0.030 |
Why?
|
| Neoplasms, Second Primary | 1 | 2015 | 24 | 0.030 |
Why?
|
| Stomach | 1 | 2015 | 19 | 0.030 |
Why?
|
| Pain Measurement | 1 | 2016 | 385 | 0.030 |
Why?
|
| Spleen | 1 | 2015 | 85 | 0.030 |
Why?
|
| Cause of Death | 1 | 2015 | 245 | 0.030 |
Why?
|
| Colon | 1 | 2015 | 72 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2014 | 33 | 0.030 |
Why?
|
| Pancreas | 1 | 2015 | 108 | 0.030 |
Why?
|
| Surgical Wound Infection | 1 | 2015 | 100 | 0.030 |
Why?
|
| Serum Albumin | 1 | 2014 | 57 | 0.030 |
Why?
|
| Comorbidity | 1 | 2015 | 596 | 0.030 |
Why?
|
| Tissue Engineering | 1 | 2019 | 700 | 0.020 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2011 | 22 | 0.020 |
Why?
|
| Track and Field | 1 | 2007 | 3 | 0.020 |
Why?
|
| Radiography | 1 | 2007 | 397 | 0.020 |
Why?
|
| Rectum | 1 | 2002 | 18 | 0.010 |
Why?
|